Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICG-PSMA is a targeted fluorescent imaging agent developed for the intraoperative visualization of prostate cancer. It consists of the near-infrared fluorescence (NIRF) dye indocyanine green (ICG) conjugated to a small-molecule ligand that specifically targets prostate-specific membrane antigen (PSMA), a protein highly expressed on the surface of prostate cancer cells. By binding to PSMA, the agent allows surgeons to identify tumor margins, lymph node metastases, and extracapsular extension in real-time using fluorescence-guided surgery systems. This approach is intended to improve the accuracy of radical prostatectomy, potentially leading to better oncological outcomes and improved preservation of urinary and sexual function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ICG-PSMA.